Recently, effects on BCMA dynamics were reported from a first-in-human phase I study evaluating GSI use in combination with a BCMA-targeted therapy in patients with multiple myeloma (n = 18 treated; ref. 10). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.